Pharmaceuticals: Pakistan Listed Pharma Sector Analysis 2024 Deregulation improved sales and margins - By Topline Research
Mar 27 2025
Topline Securities
- Pakistan listed pharmaceuticals sector’s earnings were up 3.1x to Rs24.8bn in calendar year 2024. This jump in profitability is primarily attributed to higher net sales and improved gross margins.
- Net sales increased by 15% YoY to Rs318bn in 2024, primarily driven by a increase in drug prices.
- To recall, in Feb-2024 the government approved the deregulation of non-essential drug prices, which allowed companies to increase prices without any cap as it was under previous drug policy to increase the prices of all other non-essential drugs by up to the full increase in CPI (with a cap of 10%). While prices of essential drugs are still capped with formula of up to 70% of the increase in CPI (with cap of 7%).